<DOC>
	<DOCNO>NCT01874340</DOCNO>
	<brief_summary>To evaluate efficacy safety AIN457 versus placebo patient relapse multiple sclerosis .</brief_summary>
	<brief_title>Efficacy Safety AIN457 ( Secukinumab ) Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis Multiple Sclerosis accord 2010 revise McDonald criterion Disease duration 10 year less At least one relapse last year EDSS score 0 5.0 entry Active chronic disease immune system multiple sclerosis History malignancy within past 5 year Active systemic bacterial , viral fungal infection Previous treatment one class multiple sclerosis therapy except previous treatment glatiramer acetate interferonbeta ( ) Any medically unstable condition Unable undergo MRI scan repeat blood test Pregnant nursing female Women childbearing potential must use reliable form contraception Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>AIN457</keyword>
	<keyword>Secukinumab</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Demyelinating Diseases</keyword>
</DOC>